Introduction
Epilepsies affect about 1% of the population, rendering it one of the most common neurological disorders. Most non-lesional epilepsies arise on an oligogenic or polygenic background, but several seizure disorders are known to segregate in a Mendelian fashion. These rare monogenic epilepsies are valuable models for scientific approaches and have already helped to uncover parts of the various pathomechanisms underlying epileptogenesis. Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) has a special role within this group of monogenic epilepsies because it was the first epilepsy in humans for which specific mutations were identified. So far, mutations in at least two genes, CHRNA4 and CHRNB2 encoding the a4 and b2 subunits of the neuronal nicotinic acetylcholine receptor (nAChR), are known to give rise to ADNFLE. 1, 2 These mutations cause a clinical phenotype that was initially described as a ''pure'' epilepsy characterized by nocturnal seizures that arise mostly from non-REM sleep. In the original family 27 individuals were affected and, except for the seizures, no neurological symptoms, psychiatric disturbances or mental deficiencies were reported. 3 Subsequent studies indicated that borderline intelligence or mild deficits in executive tasks are not uncommon in ADNFLE patients. 4 However, major neurological features such as schizophrenia-like symptoms, mental retardation or cognitive deficits have been described only in a few families. [5] [6] [7] [8] [9] [10] So far it is unknown if these additional features occur by chance, or if they are indeed causally related to specific nAChR mutations. The systematic analysis of the clinical variability presented here suggests that the risk for additional major neurological and psychiatric features might be increased for ADNFLE patients with certain nAChR mutations but rare for the carriers of most other mutations. The functional studies show that ADNFLE mutations differ from each other with respect to their biopharmacological characteristics but that no obvious correlation can be detected between the severity of the clinical phenotypes and the respective changes in receptor function.
Methods

Subjects
Clinical data from 20 ADNFLE families with known nAChR mutations were either taken from the histories of families diagnosed in our lab (Munich) or collected by reviewing the relevant literature (for references see Table 1 ). The study protocol was approved by the institutional review board and informed consent was given from the participants.
Mutation construct
CHRNA4 and CHRNB2 mutations were introduced by PCR-based site-directed mutagenesis (QuikChange II site-directed mutagene-Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a rare familial seizure disorder caused by mutations in at least two different subunit genes of the neuronal nicotinic acetylcholine receptor (nAChR), CHRNA4 and CHRNB2. ADNFLE was initially described as a ''pure'' seizure disorder with a mostly benign course. We have analysed the clinical features of 19 ADNFLE families from 12 countries with a total of 150 patients and grouped them with respect to their nAChR mutations. These data suggest that certain nAChR mutations might be associated with an increased risk for major neurological symptoms such as mental retardation, schizophrenia-like symptoms or marked cognitive deficits, but the risk for these disorders seems to be low for most other ADNFLE mutations. The functional data confirm that the mutations differ from each other with respect to the size of their gain-of function effects and other biopharmacological characteristics although these functional changes are not predictive for the severity of the clinical phenotype.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. ADNFLE mutations frequently associated with additional major neurological or psychiatric symptoms are given in bold. Mutations are named as in the original references, for CHRNA4 numberings according to reference sequences (NP_000735.1, NP_000739.1) are given in brackets; NA, data not available; NT, not currently treated; n, number of patients; f/m, female/male; n/t, number of total; MD, patients with more than one drug; SRI, spontaneous remission or improvement. Antiepileptic drugs (number of patients given in brackets): CBZ, carbamazepin; PB, phenobarbital; PHT, phenytoin; LTG, lamotrigine.
sis Kit, Stratagene Europe) into full-length cDNAs as previously described. 11 The correct sequences were confirmed by direct sequencing.
Functional studies
Xenopus oocytes were isolated and selected as previously described. 11 Briefly, oocytes were harvested from mature Xenopus females following animal ethic rules of Geneva canton, Switzerland. Oocytes were isolated by mechanical and enzymatic action using type I collagenase (Sigma, Basel Switzerland) at 0.2% in a medium deprived of calcium. Stage V and VI oocytes were placed in 96 wells microtiter plates (NUNC) in BARTH medium that contained 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 10 mM HEPES, 0.82 mM MgSO 4 Á7H 2 O, 0.33 mM Ca(NO 3 ) 2 Á4H 2 O, 0.41 mM CaCl 2 Á6H 2 O, adjusted to pH 7.4 with NaOH and complemented with kanamycin (20 mg/ml), penicillin (100 U/ml) and streptomycin (100 U/ml). Nuclear injections of 2 ng of cDNAs containing in equal ratios the genes of interest were performed with a robot, 12 and cells were subsequently maintained at 18 8C.
Recording of nAChR properties
Electrophysiological properties of oocytes were determined two to five days after cDNA injection by automated two electrode voltage clamp. During recording oocytes were continuously superfused with OR2 (control medium) that contained 82.5 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, adjusted to pH 7.4 with NaOH. Unless otherwise stated the holding potential was À100 mV and experiments were performed at 18 8C. Data were filtered at 10 Hz and digitized at 100 Hz with an analog to digital converter (National Instrument). Concentration-activation curves were fitted using a Hill equation in the form:
nH where: y = the fraction of evoked current, EC 50 = concentration for 50% activation of the high affinity, n H = the apparent cooperativity for the high affinity, x = agonist concentration. For statistical analysis the unpaired, two-tailed Student's t-test was computed either with Excel (Microsoft) or Matlab (mathworks Inc.).
Results
Clinical findings
The clinical information of 20 ADNFLE families from 13 countries with a total of 150 patients is summarized in Table 1 . More females than males were affected by nocturnal frontal lobe epilepsy (total, 86 versus 64, CHRNA4, 55 versus 45; CHRNB2, 23 versus 17; CHRNA2, 8 versus 2). The known mutational spectrum in ADNFLE includes five CHRNA4 and four CHRNB2 mutations (Fig. 1) . CHRNA4 mutations are located within or directly adjacent to the second transmembrane domain (TM2), while CHRNB2 mutations are equally distributed between TM2 and TM3. An exception is CHRNA4-R308H, a recently published but not yet functionally characterized mutation in the second intracellular loop. 13 A single 4 Severe additional neurological or psychiatric features were diagnosed in most carriers of CHRNA4 mutations S252L and 776ins3, [5] [6] [7] [8] [9] 23 and CHRNB2 mutation I312M. 10, 24 The CHRNA4 mutation S252L was the only one that
showed an unusual age of onset in 7/19 patients with seizures starting as early as six months of age, while the average age of onset for all other mutations was mostly within the second half of the first decade or in the second decade. Only very few patients with mutations other than S252L were reported to have an earlier age of onset. 3, 5 Additional major neurological and psychiatric features tended to be the same with a given mutation but different between mutations. Mental retardation was the main additional symptom described in 10/19 carriers of CHRNA4 mutation S252L, [6] [7] [8] 23, 25 while at least 6/11 affected family members in the CHRNA4-776ins3 family had serious psychiatric problems including schizophrenia-like symptoms (four additional affected individuals from this family refused to be questioned about psychiatric problems). 9 The CHRNB2 mutation I312M was associated with specific cognitive defects affecting mostly verbal memory in all affected members from the two families known to carry this mutation 10, 24 (Table 1) .
Electrophysiological analysis
The normalized dose-response curve of the wildtype a4b2
receptors showed a very low sensitivity for acetylcholine for doses up to 1 mM. Concentrations above 1 mM elicited currents with a steep increase in amplitude with a maximum reached at 300 mM.
In accordance to previous published studies the results were best fitted with the sum of two empirical Hill equations. 15 Compared to the wildtype the two mutations a4S248F/b2 and a4S252L/b2
showed a much higher affinity for acetylcholine, which was most pronounced in the latter mutation. Referring to the EC50H of the mutated receptors (0.8 for a4S248F/b2 and 0.75 for a4S252L/b2) they differed markedly from that of the wildtype receptor (8.5). Nonetheless the Hill coefficients for the high-affinity state as well as that for the low affinity state were nearly equal for all three receptors (n HH = 0.9-0.95 and n HL 1.4, respectively; see Table 2 ). Fig. 1 . Position of ADNFLE mutations in CHRNA4 and CHRNB2. Wild type amino acids are underlined and mutated amino acids are written above or below them. For numbering see legend of Table 1 .
Recorded currents of receptors carrying the b2 mutations, a4/ b2L301V and a4/b2V287M, were normalized and fitted as described above. The highest affinity for ACh was seen for the a4/b2V287M receptor (EC 50H = 0.4) followed by a4/b2L301V (EC 50H = 3.8) and finally the wild type a4/b2 with the lowest affinity (EC 50H of 8.4). In contrast to the alpha-subunit mutations and to the wildtype receptors, the Hill-coefficients for the highaffinity state of b2-mutations were generally higher (a4/b2L301V n HH = 1.3; a4/b2V287M n HH = 1.6) than for the low-affinity state (L301V n HL = 0.9, V287M n HL = 1.0). The number of receptors in the high-affinity state was remarkably increased for all four mutations examined in this study (see parameter ''a'' in Table 2 ).
Discussion
All but one of the known ADNFLE mutations cluster in small parts of either CHRNA4 or CHRNB2 (Fig. 1) , and several of these mutations have been identified in two or more unrelated families (Table 1) . However, phenotypic comparison is hampered by the fact that most of the published families have not been evaluated by standardized neuropsychological tests. This renders it difficult to deduce exact risk figures for additional neurological or psychiatric problems that might be associated with ADNFLE mutations. Mild cognitive deficits as they have been reported in a pilot study for a small number of patients 4 might often go undetected without careful evaluation, however, major neurological symptoms such as mental retardation or schizophrenia-like disorder are likely to be reported. The present study therefore focused solely on such major symptoms, but it needs to be stressed that for all mutations the frequency of associated clinical symptoms might in fact be higher than given in Table 1 .
Comparison of the clinical data shows that the percentage of patients reported to have associated major neurological or psychiatric features is rather low for some mutations but quite high for others. The data also suggest that these associations are not exclusive as not all carriers of mutations that seem to bear an increased risk for major neurological or psychiatric symptoms are affected by these additional features but a few carriers of putative low-risk mutations are. It is also interesting to note that families carrying the same mutation tend to have an identical pattern of accessory major neurological or psychiatric features. In some families mental retardation was a common feature but no psychiatric disorders were reported while in other families the opposite pattern was observed ( Table 1 ). The strongest association between mutation and clinical phenotype was found for a pair of mutations located close together in transmembrane region 2 (TM2) of CHRNA4, S248F and S252L. CHRNA4-S248F was the first mutation discovered in ADNFLE, 1 and has been found in an extended Australian family of British origin as well as in families from Spain, Norway and Scotland. [16] [17] [18] With a total of 67 patients it is so far the most frequently found ADNFLE mutation. The large number of patients carrying this mutation allows a good assessment of the clinical variability of major neurological symptoms associated with CHRNA4-S248F. This mutation seems to belong to the more benign causes of ADNFLE because the few carriers that have been analysed by neuropsychological tests were found to have mild cognitive deficits [4] but major psychiatric or neurological features other than epilepsy were only reported in two out of 67 patients. The age of onset is within the usual range observed for most ADNFLE mutations, and long-time remissions are not uncommon. The rather benign nature of CHRNA4-S248F contrasts sharply with the more severe clinical course that seems to be associated with the adjacent mutation CHRNA4-S252L. At least 11 of the 19 known carriers of this mutation showed intellectual capacities that fell into the low normal or the moderate retarded range. Remarkable is also the unusually low age of onset which in three out of four families with CHRNA4-S252L was mostly in early childhood (six months to two years). 6, 7, 23 The later age of onset in the third family argues against a causative relationship between the early onset of epilepsy and the less than favourable mental outcome in CHRNA4-S252L patients. 8 It seems more likely that both features are independent of each other but are both related to the underlying mutation. Another example for two adjacent ADNFLE mutations that differ with respect to their clinical features is the CHRNB2 mutations V308A and I312M. Like CHRNA4-S248F, mutation CHRNB2-V308A causes a mostly benign type of nocturnal frontal lobe epilepsy usually without additional neurological or psychiatric features. 15 The clinical spectrum associated with mutation CHRNB2-I312M appears to be much more severe with all four affected members from two unrelated families showing clinically relevant deficits in their cognitive functions, especially in verbal memory. 10, 24 However, unlike the S248F and S252L mutations described above, the numbers of families and patients with mutations V308A or I312M are still rather low and do not allow definite conclusions about the phenotypic differences yet. The families carrying the same ADNFLE mutation and sharing the same associated neurological or psychiatric features are usually from different countries and are most likely unrelated, thus a shared genetic background cannot explain the observed associations. The possibility remains that the associated symptoms are caused by a not fully penetrant mutation in a second, unknown gene. However, the probabilities that such a gene would be physically closely linked to the mutated nAChR gene or cosegregate with it in a multiplex pedigree by chance are very low, rendering these two possibilities unlikely. Another possibility would be that unknown environmental factors are responsible for the increased risk for additional major features. Again, this explanation is unlikely because the chances are very low that the same environmental risk factors are present in families carrying the same mutation but living in countries far apart. Furthermore, there are no obvious differences with respect to high drug doses or multiple drug treatment between ADNFLE families with a high versus those with a low rate of associated clinical features. A causal relationship between the neurological and psychiatric features and the respective ADNFLE mutation seems to be the most likely explanation, and it would also fit well with the wide range of neuronal dysfunctions and psychiatric disorders nAChRs have been implicated in Ref. 26 . For example, loss of cholinergic transmission is regarded as a significant cause of cognitive decline in patients with Alzheimer's disease. This hypothesis is supported by the reduction and degeneration of cholinergic neurons or the reduced amount of cholinergic key enzymes like choline acetyltransferase and acetylcholine esterase in post mortem brains of Alzheimer patients. 27 More recently, cholinergic dysfunction has been shown to be an early hallmark of cognitive decline. 28 Genetic variants in nAChR subunits have also found to be associated with psychiatric disorders and behavioural traits. 29 It can therefore be hypothesized that the dysfunction of nAChRs caused by ADNFLE mutations is probably at the origin of the additional major neurological or psychiatric symptoms observed in several of the patients suffering from this rare genetic epilepsy. Expression studies demonstrate that, despite their clustering, ADNFLE mutations significantly differ from each other with respect to the changes in biopharmacological properties they induce in receptor function. All known ADNFLE mutations have in common that, at least in vitro, they cause a gain of function effect by increasing the receptors sensitivity to acetylcholine. 15, 30 Nevertheless, the extent of this gain of function effect is not identical for each mutation (Fig. 2) , and they also display individual profiles for several other biopharmacological characteristics. This is best demonstrated for CHRNA4-S248F and CHRNA4-S252L that, coexpressed with wild type CHRNB2, differ from each other with respect to their desensitisation kinetics. When ACh test-pulses were given repeatedly while background ACh concentration was steadily raised, nAChRs with mutation CHRNA4-S248F showed a gradual increase of desensitisation while CHRNA4-S252L receptors presented with a nearly complete desensitisation already after the first test-pulse. The effect was found to be most pronounced in experimental setups that did not include wild type CHRNA4, 30 which makes it difficult to predict how pronounced the effect on desensitisation kinetics will be in vivo. Another example for functional differences between ADNFLE mutations is CHRNB2-V287M and CHRNB2-L301V. In the heterozygous state (CHRNB2-V287M/CHRNB2/CHRNA4 and CHRNB2-L301V/CHRNB2/CHRNA4, respectively) both mutations render the receptor more sensitive towards acetylcholine, but this effect is significantly stronger with CHRNB2-V287M than with CHRNB2-L301V (Fig. 2) . These mutations display considerable differences in their EC 50 values, an observation that is more obvious in their low than in their high affinity components. These two components reflect the assembly of two distinct subunit stoichiometries [a4] 3 [b2] 2 and [a4] 2 [b2] 3 , respectively. Taken together, the functional studies show that ADNFLE mutations are characterized by their highly individual biopharmacological profiles, but mutations that are frequently associated with additional major symptoms do not necessarily display larger functional changes than mutations that cause a more ''benign'' course of the disorder. So far no direct correlation has been found between the impact an ADNFLE mutation has on receptor function and the severity of the clinical symptoms.
Conclusions
The data presented here suggest that certain ADNFLE mutations might be associated with specific risks for additional major neurological or psychiatric symptoms. However, the numbers of affected families are still too low for some of these mutations and many of the families included here did not yet underwent a comprehensive neuropsychological examination. Clinicians who evaluate patients from ADNFLE families should therefore include neuropsychological testing whenever possible in order to increase our knowledge about the genotype-phenotype correlations in this rare disorder.
